CN1850863B - 针对自身抗原和/或种属间高度保守抗原的抗体及其制备方法 - Google Patents
针对自身抗原和/或种属间高度保守抗原的抗体及其制备方法 Download PDFInfo
- Publication number
- CN1850863B CN1850863B CN2006100810790A CN200610081079A CN1850863B CN 1850863 B CN1850863 B CN 1850863B CN 2006100810790 A CN2006100810790 A CN 2006100810790A CN 200610081079 A CN200610081079 A CN 200610081079A CN 1850863 B CN1850863 B CN 1850863B
- Authority
- CN
- China
- Prior art keywords
- mouse
- antigen
- protein
- antibody
- autoantigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 25
- 102000036639 antigens Human genes 0.000 title claims abstract description 24
- 108091007433 antigens Proteins 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 20
- 230000036039 immunity Effects 0.000 claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 230000001076 estrogenic effect Effects 0.000 claims description 20
- 102000055207 HMGB1 Human genes 0.000 claims description 13
- 108700010013 HMGB1 Proteins 0.000 claims description 13
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 12
- 101150021904 HMGB1 gene Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 150000005690 diesters Chemical class 0.000 claims description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- 108090000171 Interleukin-18 Proteins 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
- 239000000568 immunological adjuvant Substances 0.000 claims description 2
- 241001655218 Heterogenys Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 81
- 101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 16
- 230000008521 reorganization Effects 0.000 description 16
- 239000007943 implant Substances 0.000 description 10
- 230000004927 fusion Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 101150058224 MIF gene Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 5
- 102100032420 Protein S100-A9 Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 102000057593 human F8 Human genes 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229940047431 recombinate Drugs 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 108700031361 Brachyury Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 1
- ZSJFGGSPCCHMNE-LAEOZQHASA-N Asp-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N ZSJFGGSPCCHMNE-LAEOZQHASA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- FBCURAVMSXNOLP-JYJNAYRXSA-N His-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N FBCURAVMSXNOLP-JYJNAYRXSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
克隆号 | 4E10 | 2A12 | 10C3 |
抗体亚型 | IgG2a | IgG2b | IgG2b |
解离常数 | 1×10-9M | 1×10-10M | 3×10-9M |
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100810790A CN1850863B (zh) | 2006-05-23 | 2006-05-23 | 针对自身抗原和/或种属间高度保守抗原的抗体及其制备方法 |
PCT/CN2007/001652 WO2007134539A1 (fr) | 2006-05-23 | 2007-05-22 | Anticorps dirigé contre un auto-antigène et/ou contre une espèce d'antigène haute conservation et procédé de préparation correspondant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100810790A CN1850863B (zh) | 2006-05-23 | 2006-05-23 | 针对自身抗原和/或种属间高度保守抗原的抗体及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1850863A CN1850863A (zh) | 2006-10-25 |
CN1850863B true CN1850863B (zh) | 2012-07-04 |
Family
ID=37132365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100810790A Expired - Fee Related CN1850863B (zh) | 2006-05-23 | 2006-05-23 | 针对自身抗原和/或种属间高度保守抗原的抗体及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1850863B (zh) |
WO (1) | WO2007134539A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101891817B (zh) * | 2009-03-03 | 2012-11-07 | 中国科学院生物物理研究所 | 抗高迁移率族蛋白b-1的单克隆抗体及其应用 |
CN105801704B (zh) | 2014-12-31 | 2020-06-02 | 艾托金生物医药(苏州)有限公司 | 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179576A2 (en) * | 1984-10-19 | 1986-04-30 | Taisho Pharmaceutical Co. Ltd | Monoclonal antibody |
EP0692536A2 (en) * | 1994-07-14 | 1996-01-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | IFN-Y production inducing protein and monoclonal antibody of the same |
WO2005026209A2 (en) * | 2003-09-11 | 2005-03-24 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
-
2006
- 2006-05-23 CN CN2006100810790A patent/CN1850863B/zh not_active Expired - Fee Related
-
2007
- 2007-05-22 WO PCT/CN2007/001652 patent/WO2007134539A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0179576A2 (en) * | 1984-10-19 | 1986-04-30 | Taisho Pharmaceutical Co. Ltd | Monoclonal antibody |
EP0692536A2 (en) * | 1994-07-14 | 1996-01-17 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | IFN-Y production inducing protein and monoclonal antibody of the same |
WO2005026209A2 (en) * | 2003-09-11 | 2005-03-24 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
Non-Patent Citations (3)
Title |
---|
Audrey Tanghe et al.Immunogenicity and Protective Efficacy of Tuberculosis DNA Vaccines Encoding Putative Phosphate Transport Receptors.《The Journal of Immunology》.1999,第162卷(第2期),1113-1119. * |
Thomas J. Lang.Estrogen as an immunomodulator.《Clinical Immunology》.2004,第113卷(第3期),224-230. * |
Weiser WY et al.Generation of human hybridomas producing migration inhibitory factor (MIF) and of murine hybridomas secreting monoclonal antibodies to human MIF.《Cell Immunol》.1985,第90卷(第1期),167–178. * |
Also Published As
Publication number | Publication date |
---|---|
CN1850863A (zh) | 2006-10-25 |
WO2007134539A1 (fr) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101420983B (zh) | 包含超分子抗原构建体的组合物和方法 | |
Matthews et al. | Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. | |
Hand et al. | Production and function of immunoglobulin A | |
Uyttenhove et al. | Development of an anti‐IL‐17A auto‐vaccine that prevents experimental auto‐immune encephalomyelitis | |
ES2305110T5 (es) | Anticuerpos contra il-1 beta humana. | |
Aalberse | The role of IgG antibodies in allergy and immunotherapy | |
Guan et al. | Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis | |
US20030003440A1 (en) | Novel CCR5 epitope and antibodies against it | |
CN107660150A (zh) | Il‑18结合蛋白(il‑18bp)和抗体在炎性疾病中 | |
Sun et al. | Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice | |
JP2018193376A (ja) | 炎症性疾患の予防又は治療剤 | |
Kirsner | The historical basis of the idiopathic inflammatory bowel diseases | |
CN107427577A (zh) | 具有蛋白酶可切割接头的肽构建体 | |
US6974573B2 (en) | Antibody production in farm animals | |
Uyttenhove et al. | Development of an anti‐IL‐12 p40 auto‐vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection | |
CN1850863B (zh) | 针对自身抗原和/或种属间高度保守抗原的抗体及其制备方法 | |
CN113577257B (zh) | 细粒棘球绦虫EgTeg和EgFABP1多表位疫苗及应用 | |
Guan et al. | Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis | |
US20200016249A1 (en) | Il-23-p19 vaccines | |
Guan et al. | An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo | |
WO2003055518A1 (fr) | Procede de traitement d'etats immuno-pathologiques et medicament correspondant | |
Bäckström et al. | Bystander suppression of collagen-induced arthritis in mice fed ovalbumin | |
US5723582A (en) | Antigen-specific human glycosylation inhibiting factor | |
TWI639615B (zh) | 一種利用雙硫鍵重組技術製造抗蛇毒血清之方法及其產物 | |
ES2258483T3 (es) | Produccion de anticuerpos de secrecion mamaria en animales de granja. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20061025 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING PUSAI ASSET MANAGEMENT LLC Free format text: FORMER OWNER: BIO-PHYSICS INST., CHINESE ACADEMY OF SCIENCES Effective date: 20150416 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100101 CHAOYANG, BEIJING TO: 100190 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150416 Address after: 100190 room 4, building 3, 201 North First Street, Haidian District, Beijing, Zhongguancun Patentee after: Beijing universal Asset Management Co.,Ltd. Address before: 100101 Beijing city Chaoyang District Datun Road Research Institute of Biophysics Chinese Patentee before: Institute of Biophysics, Chinese Academy of Sciences |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170705 Address after: 528300, room 6, floor 621, building A, 2 south south of the Five Ridges Avenue, Lecong Town, Shunde District, Guangdong, Foshan Patentee after: GUANGDONG YUNTIAN ANTIBODY BIOTECHNOLOGY Co.,Ltd. Address before: 100190 room 4, building 3, 201 North First Street, Haidian District, Beijing, Zhongguancun Patentee before: Beijing universal Asset Management Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 |